Equities research analysts at StockNews.com began coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a research report issued to clients and investors on Monday. The brokerage set a "hold" rating on the stock.
LadRx Stock Performance
CYTR stock opened at $0.09 on Monday. The company has a 50 day moving average price of $0.10 and a 200 day moving average price of $0.12. LadRx has a fifty-two week low of $0.05 and a fifty-two week high of $0.86.
Get LadRx alerts:LadRx Company Profile
(Get Rating)
LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.Further Reading
- Get a free copy of the StockNews.com research report on LadRx (CYTR)
- General Electric Stock, The Sum of All Parts Strategy is Paying Off
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here's Why
Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.